Li Anchuan, Mao Miaobin, Chen Runfan, Chi Pan, Huang Ying, Wu Junxin, Xu Benhua
Department of Radiation Oncology, Fujian Medical University Union Hospital, Xinquan Road 29, Fuzhou, 350001, China.
Department of Radiation Oncology, College of Clinical Medicine, Fujian Medical University, Fuzhou, 350001, China.
Discov Oncol. 2024 Mar 16;15(1):76. doi: 10.1007/s12672-024-00885-6.
To explore the impact of excluding the external iliac node (EIN) from the clinical target volume (CTV) during preoperative radiotherapy in T4b rectal cancer with anterior structure invasion.
We retrospectively identified 132 patients with T4b rectal cancer involving the anterior structures who received radiotherapy followed by surgery between May 2010 and June 2019. Twenty-nine patients received EIN irradiation (EIN group), and 103 did not (NEIN group). Failure patterns, survival and toxicities were compared between the two groups.
The most common failure was distant metastasis (23.5%). 11 (8.3%) patients developed locoregional recurrence, 10 (9.7%) patients were in the NEIN group, and 1 (3.4%) was in the EIN group (P = 0.34). The EIN region failure was rare (1/132, 0.8%). The locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), overall survival (OS) and progression-free survival (PFS) rates were 96.3% vs. 90.5%, 82.1% vs.73.7%, 75.9% vs. 78.0% and 72.4% vs. 68.3% (all P > 0.05) for the EIN group and NEIN group, respectively. The incidence of grade 3-4 acute toxicity in the lower intestine was significantly higher in the EIN group than in the NEIN group (13.8% vs. 1.9%, P = 0.02). The Dmax, V35 and V45 of the small bowel was decreased in the NEIN group compared to the EIN group.
Exclusion of the EIN from the CTV in T4b rectal cancer with anterior structure invasion could reduce lower intestinal toxicity without compromising oncological outcomes. These results need further evaluation in future studies.
探讨在术前放疗中,对于侵犯前方结构的T4b期直肠癌患者,将髂外淋巴结(EIN)排除在临床靶区(CTV)之外的影响。
我们回顾性分析了2010年5月至2019年6月期间132例接受放疗后手术的侵犯前方结构的T4b期直肠癌患者。29例患者接受了EIN照射(EIN组),103例未接受(非EIN组)。比较两组的失败模式、生存率和毒性反应。
最常见的失败是远处转移(23.5%)。11例(8.3%)患者发生局部区域复发,非EIN组10例(9.7%),EIN组1例(3.4%)(P = 0.34)。EIN区域失败罕见(1/132,0.8%)。EIN组和非EIN组的局部区域无复发生存率(LRFS)、远处转移无复发生存率(DMFS)、总生存率(OS)和无进展生存率(PFS)分别为96.3%对90.5%、82.1%对73.7%、75.9%对78.0%和72.4%对68.3%(所有P > 0.05)。EIN组下肠道3-4级急性毒性反应的发生率显著高于非EIN组(13.8%对1.9%,P = 0.02)。与EIN组相比,非EIN组小肠的Dmax、V35和V45降低。
对于侵犯前方结构的T4b期直肠癌患者,将EIN排除在CTV之外可降低下肠道毒性,且不影响肿瘤学结局。这些结果需要在未来的研究中进一步评估。